Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 2/20 | 0.31 |
| ▸ | HTR1B | P28222 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12699692 | 0.86 | CYP3A4 (0.38) | NQO2ALDH1A1CYP3A4TSHRTDP1 | |
| Acetic Acid SCHEMBL29701131 | 0.85 | MEN1 (0.40) | ALDH1A1MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL18299850 | 0.82 | CYP3A4 (0.40) | NQO2ALDH1A1MAPK1CYP1A2CYP3A4 | |
| SCHEMBL15430818 | 0.82 | NQO2 (0.31) | NQO2 | |
| SCHEMBL31089099 | 0.82 | ALOX15 (0.36) | NQO2ALDH1A1MAPK1KDM4ECYP1A2 | |
| SCHEMBL27642248 | 0.82 | ALOX15 (0.36) | NQO2ALDH1A1MAPK1KDM4ECYP1A2 | |
| SCHEMBL17643478 | 0.78 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL19468429 | 0.78 | NQO2 (0.44) | NQO2L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL31035450 | 0.77 | SHBG (0.34) | ALDH1A1 | |
| SCHEMBL31035135 | 0.77 | ERN1 (0.44) | ALDH1A1CYP1A2CYP2D6CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108948142-B | Fluorescent probe targeting tumor cells and new vessels and preparation method thereof | 川北医学院 | 2022-02-22 | — | — | CN | claimed |
| CN-108893106-B | Fluorescent probe for detecting high-concentration gamma-glutamyl transpeptidase and preparation method thereof | 川北医学院 | 2021-03-16 | — | — | CN | claimed |
| US-10431746-B2 | Quaternized tetrazine-based donor-acceptor copolymers | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2019-10-01 | — | — | US | claimed |
| US-20180301630-A1 | QUATERNIZED TETRAZINE-BASED DONOR-ACCEPTOR COPOLYMERS | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2018-10-18 | — | — | US | claimed |
| CN-106010316-A | Adhesive for steel volute and preparation method thereof | 保定亿嘉特种陶瓷制造有限公司 | 2016-10-12 | — | — | CN | claimed |
| EP-2521722-B1 | PROCESS FOR MAKING A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR - 874 | ASTRAZENECA AB (SE) | 2015-05-06 | — | — | EP | claimed |
| CN-102643213-B | Preparation method of 3, 5-dimethyl-4-bromomethylbenzonitrile | JIMING MEDICAL TECHNOLOGY SUZHOU CO LTD | 2014-04-09 | — | — | CN | claimed |
| US-20130203995-A1 | Process for Making a Metabotropic Glutamate Receptor Positive Allosteric Modulator - 874 | ASTRAZENECA AB (SE) | 2013-08-08 | — | — | US | claimed |
| EP-2521722-A1 | PROCESS FOR MAKING A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR - 874 | AstraZeneca AB (SE) | 2012-11-14 | — | — | EP | claimed |
| CN-102643213-A | Preparation method of 3, 5-dimethyl-4-bromomethylbenzonitrile | JIMING MEDICAL TECHNOLOGY SUZHOU CO LTD | 2012-08-22 | — | — | CN | claimed |
| WO-2011084098-A1 | PROCESS FOR MAKING A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR - 874 | ASTRAZENECA AB (SE) | 2011-07-14 | — | — | WO | claimed |
| CN-122036699-A | THR-beta modulators and methods of use thereof | 阿利戈斯治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250236610-A1 | 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2025-07-24 | — | — | US | disclosed |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
| WO-2007076431-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-05 | — | — | WO | disclosed |
| US-7189790-B2 | Catalyst component for olefin polymerization, catalyst for α-olefin polymerization and process for the production of α-olefin polymer | JAPAN POLYPROPYLENE CORPORATION (JP) | 2007-03-13 | — | — | US | disclosed |
| EP-1520863-A1 | Catalyst for alpha-olefin polymerisation and process for the production of alpha-olefin polymer | Japan Polypropylene Corporation (JP) | 2005-04-06 | — | — | EP | disclosed |
| US-20050070426-A1 | Catalyst component for olefin polymerization, catalyst for alpha-olefin polymerization and process for the production of alpha-olefin polymer | JAPAN POLYPROPYLENE CORPORATION (JP) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203995-A1 | Process for Making a Metabotropic Glutamate Receptor Positive Allosteric Modulator - 874 | GRM4, GRIK4, GRIA4 | NQO2 3517/4885L3MBTL1 3380/4885ALDH1A1 3129/4885 |
| US-20050070426-A1 | Catalyst component for olefin polymerization, catalyst for alpha-olefin polymerization and process for the production of alpha-olefin polymer | COG1, MSMO1, COG4 | NQO2 4407/4885L3MBTL1 4142/4885ALDH1A1 269/4885 |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | NQO2 2914/4885L3MBTL1 1414/4885ALDH1A1 3330/4885 |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F12, F7, F2 | NQO2 3469/4885L3MBTL1 513/4885ALDH1A1 4184/4885 |
| US-20250236610-A1 | 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | HIPK1, HIPK3, HIPK2 | NQO2 2942/4885L3MBTL1 3326/4885ALDH1A1 3156/4885 |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | NQO2 1239/4885L3MBTL1 4553/4885ALDH1A1 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.